Edesa Biotech, Inc. (EDSA)

In the past six months, Edesa Biotech's stock price has declined by 29.19%. Key events include the report of Fiscal 3rd Quarter 2025 Results on August 8, 2025, positive results from a Phase 3 respiratory study announced on October 28, 2025, the announcement of an upcoming conference schedule on October 31, 2025, the report of Fiscal Year 2025 Results on December 12, 2025, and an increase in the maximum aggregate offering amount of its common shares under an existing at-the-market (ATM) offering agreement to $2.26 million on December 12, 2025.

As a clinical-stage biopharmaceutical company, Edesa Biotech's products are in clinical trials, and there is no readily available information or indication of traditional demand seasonality for its pipeline products or services. Demand for future commercialized products would likely be driven by disease prevalence and treatment efficacy rather than seasonal patterns.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for inflammatory and immune-related diseases. The company's pipeline includes EB05, being evaluated in a Phase 3 study for Acute Respiratory Distress Syndrome (ARDS); EB07, targeting pulmonary fibrosis and systemic sclerosis; EB01, for allergic contact dermatitis; and EB06, an anti-CXCL10 monoclonal antibody candidate for vitiligo.

Edesa Biotech is headquartered in Markham, Ontario, Canada, and maintains research facilities in Cambridge, Massachusetts. The company serves global markets through strategic alliances in North America, Europe, and Asia.

Edesa Biotech's reputation is influenced by its clinical progress and analyst sentiment. Positive results from a Phase 3 respiratory study and favorable final results from a Phase 2b dermatitis study contribute positively. However, a stock price decrease of 21.28% over the last 12 months and 29.19% in the past six months could negatively impact investor perception. Analyst ratings hold a consensus "Hold" rating, with an average price target of $5.00, representing a potential upside of 233.33% from its current price.

Edesa Biotech's ownership is a mix of institutional, insider, and retail investors. Institutional shareholders hold approximately 32.25% to 34.52% of the stock, insiders own between 16.49% and 109.60%, and retail investors hold approximately 50.09%. Pardeep Nijhawan is the largest individual shareholder, owning 71.49% of the company's shares. Other significant individual owners include Der Velden Peter Van and Thomas A. Satterfield, Jr. Major institutional owners include Stonepine Capital Management, LLC, Rubric Capital Management LP, Velan Capital Investment Management LP, Nantahala Capital Management, LLC, Vanguard Group Inc, Geode Capital Management, Llc, Commonwealth Equity Services, Llc, Renaissance Technologies Llc, FSMAX - Fidelity Extended Market Index Fund, and VEXMX - Vanguard Extended Market Index Fund Investor Shares.